Abstract: The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.

Abstract: The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.

Abstract: A method for producing a cell composition according to an embodiment of the present disclosure includes separating and obtaining mononuclear cells and autologous plasma from human peripheral blood, coating a cell culture vessel with anti-CD3 antibody, and seeding the monocytes into the cell culture vessel and culturing the same in a medium containing at least one selected from the group consisting of IL-2, IL-12 and IL-18. The cell composition may have a proportion of interferon-gamma expressing cells that has increased to 60% or more among total cells, and as the proportion of cells continuously producing interferon-gamma is increased, atopic dermatitis can be significantly improved. In addition, it is expected that it will be possible to fundamentally treat immunological abnormalities of atopic dermatitis because the composition has no side effects and can be safely used for a long period of time.

Abstract: The present disclosure relates to compositions and methods for treating ocular conditions or diseases with low or poorly water-soluble therapeutics incorporated into a hydrogel. In particular, the disclosure relates to non-blurring, therapeutic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.

Abstract: The present disclosure relates to compositions and methods for treating ocular diseases with antibiotics. In particular, the disclosure relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye and do not interfere with wound healing.

Abstract: A printed circuit board disclosed. One embodiment of the present invention provides a printed circuit board that includes: an insulation layer having multiple layers of circuit wirings formed therein; a via formed along a perimeter of the insulation layer and configured for connecting circuit wirings formed on different layers of the insulation layer, the via being formed in such a way that an inside thereof is hollow; and an electromagnetic wave absorbing part contained in the via.

Abstract: A printed circuit board disclosed. One embodiment of the present invention provides a printed circuit board that includes: an insulation layer having multiple layers of circuit wirings formed therein; a via formed along a perimeter of the insulation layer and configured for connecting circuit wirings formed on different layers of the insulation layer, the via being formed in such a way that an inside thereof is hollow; and an electromagnetic wave absorbing part contained in the via.